Canopy Growth (TSX:WEED) Tanks Again: How Low Could the Stock Go?

Canopy Growth just reported weak quarterly results. What’s next for this cannabis stock?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth (TSX:WEED)(NASDAQ:CGC) is down 17% for the day at the time of writing, hitting a new multi-year low under $6 per share. Investors who stayed on the sidelines during the rout over the past 15 months are wondering if Canopy Growth stock is finally oversold and undervalued.

Canopy Growth results

Canopy Growth reported weak results for its latest quarter. The business saw net revenue drop 25% to $111.8 million from $148.4 million in the same period last year. The big hit came as global cannabis sales plunged from $101.3 million to just $66 million. Canopy Growth’s other consumer products sales, including the drinks business, generated more stable results with revenue coming in at $45.8 million compared to $47.1 million in the same three months last year.

Canopy Growth reported a net loss of $575 million, or $1.46 per share, for the latest quarter. The net loss in the same period in the previous year was worse at $700 million.

Management is still optimistic on the business with a goal of reaching profitability in 2024. The company is trimming costs and focusing on key strategic markets. Canopy Growth cut 250 jobs in a recent downsizing and has reduced its retail footprint by closing stores and exiting some international markets.

Opportunities

The entire cannabis industry is hoping the U.S. will eventually legalize the sale of cannabis products at the federal level. So far, only a handful of states allow the sale of cannabis products.

Over the past couple of years, the sector has rallied on hints that the move is on the way, but the reality is that it could still be quite a while. However, assuming cannabis will eventually be legalized in the U.S. at the federal level, Canopy Growth is positioned well to capitalize. The company, through strategic acquisitions, has established the scale and reach to quickly take advantage of the opening of the American market.

At home, cannabis-infused drinks have not taken off as expected in Canada. That could change in 2022 and 2023 as the end of pandemic restrictions brings the return of festivals, where Canopy Growth and its peers can showcase the products.

Challenges

The black market continues to be a formidable competitor in Canada for legal cannabis products. Canopy Growth has also had to change its product offerings to accommodate shifts in consumer preferences. In what is essentially a commodity market, making money could prove to be difficult in the next few years.

Should you buy Canopy Growth stock now?

The trend isn’t an investor’s friend today and many people have been burned trying to catch this falling knife. Investors might be able to pick up a quick gain on a rebound, but I would keep any speculative bets small at this point.

The turnaround process is going to take time and the next quarterly results might not show much of an improvement.

Canopy Growth’s major shareholder, Constellation Brands, appears committed to seeing the business succeed. That’s positive for shareholders and the financial support from the drinks giant should ensure Canopy Growth survives. The risk for investors, however, is that Constellation Brands might decide to take Canopy Growth private. Depending on the price it pays, investors hoping for a rebound to recoup losses might get burned.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands. Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »